Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ERN1 | O75460 | 4/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21367494 | 0.80 | ERN1 (0.53) | CYP3A4MAPTERN1KDM4E | |
| SCHEMBL30777445 | 0.80 | ERN1 (0.53) | CYP3A4MAPTERN1KDM4E | |
| SCHEMBL21584111 | 0.73 | ERN1 (0.36) | CYP3A4MAPTERN1 | |
| SCHEMBL30777448 | 0.72 | BCL2L1 (0.42) | ERN1 | |
| SCHEMBL5367901 | 0.69 | PIM1 (0.43) | ERN1 | |
| SCHEMBL10609480 | 0.69 | CYP3A4 (0.52) | CYP3A4MAPTERN1USP2KDM4E | |
| SCHEMBL1506612 | 0.68 | BCL2L1 (0.47) | ERN1 | |
| SCHEMBL12035880 | 0.67 | TRIM24 (0.40) | ERN1KDM4EPTGS2RAB9A | |
| SCHEMBL21367505 | 0.66 | ERN1 (0.42) | CYP3A4MAPTERN1KDM4EALOX5 | |
| SCHEMBL31648926 | 0.66 | CYP3A4 (0.48) | CYP3A4MAPTERN1USP2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246931-A1 | COMPOUNDS AS PD1/PD-L1 INHIBITORS AND METHODS THEREOF | Jubilant Prodel LLC (US) | 2024-07-25 | — | — | US | disclosed |
| CN-117729921-A | Compounds and methods as PD1/PD-L1 inhibitors | 朱比兰特普罗德尔有限公司 | 2024-03-19 | — | — | CN | disclosed |
| EP-4326272-A1 | COMPOUNDS AS PD1/PD-L1 INHIBITORS AND METHODS THEREOF | Jubilant Prodel LLC (US) | 2024-02-28 | — | — | EP | disclosed |
| CN-112105610-B | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation | 朱比连特普罗德尔有限责任公司 | 2024-01-26 | — | — | CN | disclosed |
| US-11529341-B2 | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation | Jubilant Prodel LLC | 2022-12-20 | — | — | US | disclosed |
| US-11529341-B2 | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation | Jubilant Prodel LLC | 2022-12-20 | — | — | US | disclosed |
| WO-2022224278-A1 | COMPOUNDS AS PD1/PD-L1 INHIBITORS AND METHODS THEREOF | Jubilant Prodel LLC (US) | 2022-10-27 | — | — | WO | disclosed |
| WO-2022224278-A1 | COMPOUNDS AS PD1/PD-L1 INHIBITORS AND METHODS THEREOF | Jubilant Prodel LLC (US) | 2022-10-27 | — | — | WO | disclosed |
| US-20210015810-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION | Jubilant Prodel LLC | 2021-01-21 | — | — | US | disclosed |
| US-20210015810-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION | Jubilant Prodel LLC | 2021-01-21 | — | — | US | disclosed |
| EP-3765453-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION | Jubilant Prodel LLC (US) | 2021-01-20 | — | — | EP | disclosed |
| CN-112105610-A | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation | 朱比连特普罗德尔有限责任公司 | 2020-12-18 | — | — | CN | disclosed |
| WO-2019175897-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION | JUBILANT BIOSYS LIMITED (IN) | 2019-09-19 | — | — | WO | disclosed |
| WO-2019175897-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION | JUBILANT BIOSYS LIMITED (IN) | 2019-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210015810-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION | CD274, PDCD1, PDCD1LG2 | CYP3A4 89/4885MAPT 147/4885ERN1 2506/4885 |
| US-20240246931-A1 | COMPOUNDS AS PD1/PD-L1 INHIBITORS AND METHODS THEREOF | CD274, PDCD1, PDCD1LG2 | CYP3A4 1911/4885MAPT 1643/4885ERN1 1997/4885 |
| US-11529341-B2 | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation | CD274, PDCD1, PDCD1LG2 | CYP3A4 89/4885MAPT 147/4885ERN1 2506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.